Study of a new drug for pulmonary arterial hypertension
Part of Lungs & breathing clinical trials.
This trial tests an investigational drug called NS-863 for people with pulmonary arterial hypertension (PAH), a condition of high blood pressure in the lungs. The study aims to see if the drug can improve symptoms and exercise ability.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been diagnosed with a specific type of PAH (idiopathic, heritable, drug/toxin-induced, connective tissue disease-related, or repaired congenital heart disease).
- You are in World Health Organization functional class II, III, or IV (meaning you have some symptoms with daily activities or at rest).
- You are on stable background PAH therapy for at least 90 days (or 180 days for certain drugs).
- You can walk at least a certain distance in 6 minutes (as determined by the study team).
- You agree to use contraception if applicable.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental drug called HS235 for people with pulmonary arterial hypertension (PAH), a condition of high blood pressure in the lungs. It aims to see if the drug can help improve symptoms and exercise ability.
This study tests a new medicine called IKT-001 for people with pulmonary arterial hypertension (PAH). It aims to see if IKT-001 helps improve exercise ability and other symptoms when added to current PAH therapies.
This study tests a new treatment called sotatercept for people with pulmonary arterial hypertension (PAH), a condition where the blood vessels in the lungs are narrow, making the heart work harder. The goal is to see if this medicine can help improve symptoms and daily function.
This Phase 2 trial tests sotatercept, a medicine that targets the blood-vessel changes in pulmonary arterial hypertension (PAH), in children. It may help improve how well the heart and lungs work by changing the underlying disease process.
This trial tests a new oral medication, called CS1, that is added to your current PAH medications. The goal is to see if it helps improve your symptoms and ability to exercise.
This trial tests an investigational drug called NS-863 for people with pulmonary hypertension (high blood pressure in the lungs) that is caused by interstitial lung disease (scarring of the lungs). The study will check if the drug is safe and effective in improving your condition.
Hear when a new Pulmonary Arterial Hypertension trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.